Archive for the ‘Personalized Medicine’ Category

Call for Posters

You can also present your research on a poster while attending the meeting. Submit an abstract for consideration now!

Poster Submission Deadline: 23 September 2015

Exhibition Team, exhibitors@selectbio.com +44(0)1787 315110

Samir Hanash, Director of Red & Charline McCombs Institute for the Early Detection & Treatment of Cancer, University of Texas MD Anderson Cancer Center Sherry Yang, Chief, National Clinical Target Validation Laboratory, National Cancer Institute Jeremy Segal, Director, University of Chicago Valerie Taly, Group Leader/Researcher, Universite Paris Descartes Reinhard Buettner, Director, University Hospital Cologne Catherine Alix-Panabieres, Associate Professor, University Medical Center of Montpellier Julia Stingl, Professor/Director of the Division of Research, BfArM Federal Institute for Drugs and Medical Devices Edith Schallmeiner, Global Team Director - NPT, Novartis Arijit Chakravarty, Director, Takeda Pharmaceuticals Co Ltd Ryan Richardson, Healthcare Investment Banking Associate, J.P. Morgan Leeza Osipenko, Associate Director, National Institute for Health and Care Excellence

See the rest here:
SELECTBIO - Personalized Medicine and its Impact in the Clinic

NEW YORK, June 23, 2015 /PRNewswire/ --

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 270 tables & figures over 254 pages. The personalized medicine (global) market is presented as follows:

By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) By Geography (US, UK, EU) By Segment (Targeted therapeutics, Companion Diagnostics, Esoteric tests, Esoteric lab services) By Sub-market (Companion diagnostics & therapeutic, nutrition & wellness, medical technology, pharmacogenomics, consumer genomics)

A wealth of financial data & business strategy information is provided including:

Company financials, sales & revenue figures Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies Business Model Strategies for Providers. Provider Systems and Academic Medical Centres Business Model Strategies for Payers & Governments Private and Public Funding and Personalized Medicine Reimbursement Revisions to Current Payment Systems and intellectual property How to Gain Market Penetration in the EU Cost-effectiveness and Business Value of Personalized Medicine Consumer genomics and POC market Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) Comprehensive account of company product portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

Key strengths, weaknesses and threats influencing leading player position within the market Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) Top fastest growing market segments and emerging opportunities Top pharmaceutical companies within the IPM by market share and revenue Comprehensive product portfolios, R&D activity and pipeline therapeutics M&A activity and future strategies of top personalized medicine pharmacos Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy) CE-marked Personalized Medicine/Diagnostic Tests FDA Advances in Personalized Medicine Regulation

This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy.

23andMe Affymetrix Astex Pharmaceuticals Atossa Genetics CuraGen Celera Corporation (Quest Diagnostics) Celldex Therapeutics deCode Genetics (Amgen) Illumina Genelex Myriad Nodality Qiagen What you will gain:

An in-depth understanding of the global personalized medicine market and it's environment Current market facts, figures and product lines of key players in the industry Emerging trends in key markets such as the US, UK, Germany and France Knowledge of how the personalized medicine market will integrate into the global healthcare market Technical insights into new generation sequencing technologies and ultra-high throughput sequencing Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies FDA approved pharmacogenetic tests and recognized biomarkers Information on key government and regulatory policies Strategies on how to adapt and restructure current business models to this industry

Read more from the original source:
Personalized Medicine, Targeted Therapeutics and Companion ...

Empowered by genetic information, Vanderbilt aims to reinvent health care. by Bill Snyder and Dagny Stuart

The iconic Norman Rockwell painting of a family doctor checking the heart of a young patients doll may seem quaint, but its far from old-fashioned. On the contrary, personalized medicine is bringing the family doctor back and the family nurse, and the family pharmacist, and a whole team of family health care providers. Only this time, they will be empowered by 21st-century tools like genomics, informatics and high-tech imaging.

Ailments will be diagnosed more quickly and accuratelyor prevented before they can occur. By selecting drugs that match each patients unique genetic readout or by tweaking molecular pathways instead of blasting away like a shotgun, treatments will be more effective and will have fewer side effects.

After having gone through a period where blockbuster drugs and massive screening were the norm, we are actually moving back to a place where were trying to tailor care to the individual, says Dr. Jeff Balser, Vanderbilt Universitys vice chancellor for health affairs and dean of the School of Medicine.

I try to think of this as not getting more high-tech and therefore more distant from the patient, Balser says. But through technology were becoming more familiar with our patients as individuals and, along with that, always remembering to be personableNorman Rockwell with a DNA sequencer.

In 2010 Vanderbilt University Medical Center launched two major personalized medicine initiatives to advance cancer treatment and to individualize and improve drug therapy. Already this approach is showing promise.

Patients scheduled for cardiac or orthopedic procedures are being tested in advance for genetic variations that can affect their response to common blood thinners. Based on the test results, their doctors may adjust the dose or order a different drug entirely.

Similarly, by reading the genetic fingerprints of tumors removed from patients with certain forms of cancer, doctors can choose targeted drugs that are most likely to work.

Using genetic information to guide drug therapy is just the beginning. In the near future, genomicsthe science of reading and interpreting the DNA sequencewill help Vanderbilt physicians select the best tests and procedures for their patients. Eventually, genetics will help guide efforts to prevent disease and maintain good health.

Personalized medicine is more than genetics, of course. Social, family and behavioral factors, as well as environmental and economic circumstances, also have a profound impact on health. Those things are just as important in tailoring care to the individual as their genetic background, says Balser. Its almost like genomic medicine is what were using to learn how to individualize medicine, but then we can apply it to a broader set of data and circumstances.

Read the original post:
The Promise of Personalized Medicine - Vanderbilt Magazine

Personalization is threaded into the social fabric of America. Innovation is rooted in customizing and personalizing even the smallest parts of our lives, stemming from technology and retail to travel, media and wellness. The future continues to promise even smarter applications where personalization fits, but what about our health? Enter, precision medicine -- this new era of personalized medicine has arrived to healthcare and the possibilities in treating cancer unimaginable just a few years ago, are closer than ever. Imagine a world where your treatment was tailored to you, taking into consideration every cell and gene throughout your individual genetic profile, using that data to specifically design a treatment to fight the exact cancer you have? Sound too good to be true? Think again. The future is here, and the healthcare industry is preparing for massive disruption but for once disruption couldn't have come at a better time.

The Road to Personalized Medicine for Cancer Treatment

For decades, physicians had the same approach for all patients with the same type of cancer, be it breast, lung, liver or prostate cancer, the same way, even through they were aware drug treatments may work on some and fail in others. This is not to say all cancers are treated the same, but the basic approach and process is used when it comes to diagnosing, staging, and recurrence. As significant advances in research progressed over the course of the last 30 years, the medical community created standards of care and treatment when it came to diseases like diabetes, heart disease, and even cancer. However, treating cancer cannot be classified with a standard approach. What we're learning more and more comes down to the individual. Each person is as unique on the inside as they are on the outside. Therefore, why wouldn't we treat their cancer using an individual approach?

For the last 20 years, cancer cells have outsmarted us by protecting themselves, building a wall, not allowing the immune system to identify and kill them. Current treatments are not aimed at stopping cells from spreading and have almost no selective capacity to distinguish between cancer cells and healthy cells. We've basically poisoned the body to kill cancer using chemotherapy and even radiation. But advancements in research has led to a number of potential targeted therapies designed to fight cancer, among them one approach is gaining more and more support -- immunotherapy. This type of targeted therapy teaches our own immune system to fight cancer cells and spare healthy ones. By injecting bacteria inside cancer cells and putting them back into the body, the immune system can learn to recognize and kill them. Think of your T cells as guided missiles aimed at killing the bad cancer cells versus a bomb that kills every cell in its path such as chemotherapy. But an approach we could've never foreseen 10 years ago is right around the corner, leading a transition not just from the diagnosis and treatment of these cancers but much more emphasis on prediction and prevention.

Welcome to the world of precision medicine also deemed "personalized medicine," where each patient is treated individually based on their genetic makeup and the specific genetic mutations present in their body. The National Institutes of Health defines precision medicine as an emerging approach for disease treatment and prevention that integrates an individual's variability in genes, environment and lifestyle. To take it even further, precision health may be the new approach to medicine, rooted in prevention and prediction of various diseases while also maintaining overall health and quality of life.

In my field, which is prostate cancer, we talk a lot about an individual patient's risk factors such as family history, which is a huge proponent of the disease and how aggressive it is. While oftentimes surgery is the first line of defense, the right way to treat prostate cancer and any cancer is through individualized care. Recently at the 110th Annual Scientific Meeting of the American Urological Association, a significant study was presented which showed a combined assessment of genetic bio markers and the genetic profile for a patient would lead to better methods for diagnosing, treating and measuring the likelihood of the disease recurring. The breakthrough here is the role genetic testing plays in cancer, throughout the entire process, from diagnosis to recurrence. We can gather more information about the patient at each step of the way.

Precision Medicine Meets Individualized Care

I've always spoken about the importance of individualized care, especially when it comes to diagnosing and treating cancer. Innovations in genomic testing are leading this emerging era of cancer therapy -- analyzing a group of genes and their activity, which can influence how a cancerous tumor is likely to grow and respond to treatment. This type of diagnostic testing analyzes and detects very specific abnormalities in the tumor cells in a patient's individual cancer. Unlocking the mysteries of genetics holds the promise of finding more customized cures with drugs that attack genetic mutations or repair genetic defects based on the individual patient. Advances in genetic sequencing has increased the likelihood of detecting mutations driving tumor growth and even specific cells inside the tumor. This is the future of treating and diagnosing cancer, integrated with the promise of precision medicine.

Is this revolutionizing everything we know about cancer, from prevention and diagnosis to treatment and recurrence? I would say yes. We've always identified cancer based on the organ it originates in such as the prostate, colon or liver, grouping these together as if they grow the same. What we know now is just because it's deemed "prostate cancer" doesn't mean all prostate cancers develop or progress in the same way. Testing the genetics of an individual patient has opened up an entire new conversation in oncology leading us to define within the cancer what actually drives its development and progression.

The Precision Medicine Initiative

Link:
Conquering Cancer: Personalized Medicine Is the Future ...

The American health-care industrys pivot to personalized medicine has attracted the interest of an unlikely group of companies government contractors.

As health-care providers explore this new model of treatment, which involves the study of the human genome to provide personalized care, they face a problem with which many in government are familiar: analyzing an overwhelming amount of data.

Were literally drowning in data, said Norman Sharpless, an oncologist and director of the University of North Carolinas Lineberger Comprehensive Cancer Center.

The amount of information generated from sequencing human genes is growing at a rapid clip, and it has triggered a rush of clinical trials aimed at linking that knowledge to medical treatment. Cataloguing all this new information requires computational power and sophisticated analysis, Sharpless said.

For IT contractors, many of which are based in the Washington region, the flood of information presents a simple business opportunity: The same skills used to crunch massive amounts of data for cyberthreats or warfare intelligence can be applied to personalized medicine.

The governments growing interest in this field also is a factor.

In his State of the Union speech this year, President Obama outlined an initiative to explore the uses of precision medicine. His budget includes a request for $215million to fund research in this area. The White House also hired its first chief data scientist, DJ Patil, who has made precision medicine one of his priorities.

Many contractors, especially those in information technology, have been eager to pursue opportunities in precision medicine as they look to add lines of business to make up for cuts in other parts of the federal budget as overall spending slows.

That is why so many different kinds of businesses including defense giants Lockheed Martin and Northrop Grumman, and cloud storage providers such as Amazon Web Services and Google are getting in on the game.

Lockheed Martin announced a partnership this year with Illumina, a San Diego company that provides relatively inexpensive genome sequencing technology, to study the DNA of populations and develop personalized health-care solutions. For Illumina, the partnership offered access to Lockheeds experience in managing large-scale information systems, Alex Dickinson, Illuminas senior vice president of strategic initiatives, said at the time.

Read the rest here:
Personalized medicine could mean big business for D.C ...

Personalized medicine and pharmacogenomics Pharmacogenomics holds the promise that drugs might one day be tailored to your genetic makeup. By Mayo Clinic Staff

Modern medications save millions of lives a year. Yet any one medication might not work for you, even if it works for other people. Or it might cause severe side effects for you but not for someone else.

Your age, lifestyle and health all influence your response to medications. But so do your genes. Scientists are working to match specific gene variations with responses to particular medications.

With that information, doctors can tailor treatments to individuals. That's what pharmacogenomics is all about. Part of a new field called personalized medicine, pharmacogenomics offers the promise of predicting whether a medication is likely to help or hurt you before you ever take it.

Imagine you've had a heart attack and your doctor wants to give you medication to lower your risk of having another. Taking into account such factors as your weight, age and medical history, your doctor might prescribe a blood-thinning drug to help prevent blood clots from causing another heart attack.

Without testing, neither you nor your doctor knows exactly how you'll react to the medication. It may not work for you, or you may have serious side effects such as bleeding. You might have to try different doses or even different medications before finding a treatment that works for you.

Pharmacogenomics speeds up that process. Before you take a single dose of medication, you can have a test to see how you're likely to respond to the medication. With that information, your doctor can tailor the dose or avoid that drug entirely and prescribe a different one.

.

See the original post here:
Personalized medicine and pharmacogenomics - Mayo Clinic

Personalized Medicine: The Background

Personalized medicine is an extension of traditional approaches to understanding and treating illness. Since the beginning of the study of medicine, physicians have employed evidence found through observation to make a diagnosis or to prescribe treatment. In the past, this was presumably tailored to each individual, but personalized medicine makes treatment more specific.

In the modern conception of personalized medicine, the tools provided to the physician are more precise, probing not just the obvious, such as a tumor on a mammogram or cells under a microscope, but the very molecular makeup of each patient. Looking at the patient on this level helps the physician get a profile of the patients genetic distinction, or mapping. By investigating this genetic mapping, medical professionals are then able to profile patients, and use the found information to plan out a course of treatment that is much more in step with the way their body works. Genomic medicine and personalized medicine use genetic information to prevent or treat disease in adults or their children.

Having a genetic map or a profile of a patients genetic variation can then guide the selection of drugs or treatment processes. This can be used to minimize side effects or to create a strategy for a more successful outcome from the medical treatment. Helping the physician cover all the bases is imperative. Genetic mapping can also indicate the propensity to contract certain diseases before the patient actually shows recognizable symptoms, allowing the physician and patient to put together a plan for observation and prevention.

The ability to profile how genes are put together in sequence and expression level is helping to redefine the ways in which medical professionals classify diseases and discover treatments, allowing physicians to go beyond the "one size fits all" model that may be ineffective or have undesirable side effects. Through further organization, and the use of personalized medicine, medical professionals are developing many sub populations for complex diseases and physical conditions such as these.

Personalized medicine may be able to help the medical community make the most effective clinical decisions for each patient on an individual level.

Personalized medicine, when coupled with personal pharmacogenetics, is a unique approach that may be well suited for the health challenges we face in the new millennium. Although the medical and scientific communities, through research and discovery, got the upper hand over many of the diseases weve encountered since the advent of advanced medicine, we are still threatened by many more complicated diseases.

Diseases like Diabetes, heart disease, cancer and Alzheimers are thought to caused by a combination of genetic and other factors. Coupled with the fact that they tend to be chronic, they place a significant burden on not only the patient, but on the healthcare system as a whole. Personalized medicine aims to provide the tools and knowledge to fight chronic diseases and treat them more effectively than ever before.

Genetic profiles can help physicians to better discern subgroups of patients with various forms of cancer in addition to other complex diseases, helping to guide doctors with accurate forms of predictive medicine and preventative medicine. With personalized medicine, the physician is intending to select the best treatment protocol or even, in many cases, avoid passing the expense and risks of unnecessary medical treatments on to the patient altogether. Also, personalized medicine, when used correctly, aims to guide tests that detect variation in the way individual patients metabolize various pharmaceuticals. Personalized medicine is working to help determine the right dose for a patient, helping to avoid hazards based on familial history, environmental influences, and genetic variation.

Continue reading here:
Personalized Medicine - Information and Resources

Given the nature of personalized medicine, the FDA places high priority on helping to ensure that the agency, drug manufacturers, physicians and patients have adequate information about the product and its use. Product labeling and tracking of use in the marketplace are critical to the proper application of personalized medication tools.

Product Labeling

The FDA requires product labeling to be balanced, scientifically accurate and not misleading, and that clear instructions be communicated to healthcare practitioners for drug prescribing and/or administration. Personalized medicines that may only be safe and effective in particular sub-populations, or must be administered in different doses in different sub-populations, must be labeled accordingly. To date, the labeling of more than 100 approved drugs contain information on genomic biomarkers (including gene variants, functional deficiencies, expression changes, chromosomal abnormalities, and others).

Post-market Surveillance

While personalized medicine will likely allow for more focused clinical trials by increasing the proportion of responders in the trial or increasing the average effect size, or both, one implication of dramatically smaller pre-market exposure is a general increase in the importance of and emphasis on post-market monitoring, because relatively rare adverse events, in particular, are unlikely to show up when a drug is being tested in a small population, may arise when a broader population is treated. Post-market surveillance, then, is critical to the success of personalized medicine.

For more information:

Read more:
Personalized Medicine - Food and Drug Administration

Policy Updates "Precision Medicine" Proposal Includes $215M for NIH, FDA, ONC

President Obamas Precision Medicine Initiative, which he unveiled on Jan. 30, will account for $215 million in his budget proposal. The funds will be divided between the National Institutes of Health (NIH), FDA and the Office of the National Coordinator for Health Information Technology (ONC), with the majority of the money being used for the development of a voluntary national research cohort. Read PMC's press release on the initiative Watch Obama's announcement of the initiative View the White House fact sheet

21st Century Cures Draft Tackles Device Review Pathways, Biomarkers Among other topics, the U.S. House Energy & Commerce Committee's recently released "21st Century Cures" draft bill tackles innovative device review pathways and biomarker qualification. Access a summary of the bill

Senate HELP Committee White Paper Explores FDA, NIH Processes The U.S. Senate Health, Education, Labor & Pensions (HELP) Committee's recent white paper explores how well FDA and the National Institutes of Health (NIH) processes support innovation. Download the white paper

In its response letter to FDA on the agency's proposed framework for regulating laboratory-developed tests (LDTs), PMC suggests that the agency publish draft guidance documents on risk classification and Clinical Laboratory Improvement Amendments (CLIA) harmonization alongside a second draft of the original framework documents. Download the Letter

PMC Joins Stakeholders for "Precision Medicine" Announcement PMC's Amy Miller joined stakeholders at the White House on Jan. 30 when Obama announced his "Precision Medicine Initiative." Watch the announcement

PMC Engages 21st Century Cures PMC advocates for additional draft guidance documents from FDA in this 21st Century Cures response letter. Download the letter

PMC Analysis: 20 Percent of 2014 Approvals Personalized Medicines A PMC analysis of FDA's 2014 novel new drug approvals shows that more than 20 percent were personalized medicines. Download the analysis

PMC Summarizes 2014 In this blog post, PMC's Amy Miller reflects on 2014, which she calls "the year of the patient." Read the post

Go here to see the original:
Personalized Medicine Coalition precision medicine

Articles

Personalized medicine has a vision to avoid a costly and prolonged trial and error approach that can leave the patient anguishing unnecessarily from side effects, while simultaneously losing precious time in the fight against the disease. As evidence of the benefits of personalized medicine continue to grow, a network of laws, policy, education, and clinical information is building around personalized medicine to support its use in the medical community.

Personalized medicine introduces new treatment protocols, which create the ability to use molecular tracking elements that signal the risk of disease on a genetic level. This alerts the medical community to its presence before clinical indications and symptoms appear. This healthcare strategy is focused on preventive medicine and intervention, rather than a reaction to highly developed stages of disease. Such a strategy intends to delay disease onset and help the patient avoid mounting healthcare costs.

The cost of healthcare in the United States is on an upward climb, which is highly unsustainable. Proponents of personalized medicine believe that by following the practice of personalized medicine and working it into the existing healthcare system, we as a nation can resolve many of the inefficiencies inherit therein. These inefficiencies, such as a dosing system based on trial and error, severe reactions to a drugs, reactive treatment, and poorly timed diagnoses are contributing to mounting healthcare costs.

There are specific examples that the pharmacogenic system of personalized medicine is generating tangible results. Authors of various studies exploring potential healthcare cost savings from using genetic testing estimated that the use of a genetic test to properly dose various pharmaceuticals could reduce overall healthcare costs.

The substantiation of the benefits of personalized medicine is accumulating rapidly, and the real world applications of this knowledge are beginning to take root as well. Three areas of technology are key to making personalized medicine a presence in our healthcare system. New tools to decode the human genome, large-scale studies that help link genetic variation to disease, and a healthcare information technology system that supports the integration of clinical data in addition to the research is spawned from, as well as the ability of physicians to track every aspect of patient care according to genetic and molecular profiles to facilitate tailoring of treatment.

In addition, technological advancements have enabled personalized medicine to be brought to the public through the use of personal genetic testing. The systems for sequencing DNA or checking for genetic variation are essential to progress in both research and doctor to patient applications. DNA microscopes borrow technology from circuit manufacturing, helping scientists detect hundreds of thousands of genetic variations on a single chip. They are instrumental in identifying which variations are associated with any given disease.

In the last five years, the number of changes in single DNA chemical building blocks of the genome, which can be examined in a 1 cm chip increased from 250,000 to 920,000. It is estimated that there are millions such variations in the human genome. There are many subfields that are being employed as possible tools in the study of personalized medicine. Genomics and Transcriptomics offer information on genetic variation as well as the level of gene expression. Metabolomics examines the small molecules that are the byproducts of chemical reactions within the human body. Proteomics examines the entire formation of proteins made by cells. These tools are very important because what was once thought to be a single disease characterized by a common set of physical signs, for instance, asthma or breast cancer and symptoms may be several distinct conditions, or it may be a single disease with a variety of handling options.

Those in favor of personalized medicine see a future in which each person, on the day of their birth, is provided with his full genomic sequence to place into a personal medical record. That information from a personal genome would then be used to allow physicians to develop a more proactive healthcare approach based on the patients susceptibility to different diseases. The reactions to pharmaceuticals and reactions to different types of medicine would be assisted with that information as well. Advances in genomic sequencing are clearly on an exponential curve, and many scientists believe that with the help of venture capital we will see a dollar amount applied on a genome in the coming years.

Within the past few years, a growing number of businesses have begun to offer direct to consumer genetic tests. These tests are designed to help individuals better understand their genetic predisposition for a given health condition. As supporting technology has become less exclusive, genomics companies have started on the track to offer consumers whole genome scanning and associated information on individual genetic predisposition for a wide-ranging list of conditions concurrently.

Read this article:
Personalized Medicine - Articles

California sees opportunities in personalized medicine. Earlier this month, Governor Brown announced the creation of a two year initiative California Initiative to Advance Precision Medicine to begin building infrastructure and assembling resources necessary to advance precision medicine-orientated data, tools and applications. See California Launches Initiative to Advance Precision Medicine. Continue reading this entry

President Obamas precision medicine initiative earmarked over $200 million from his proposed 2016 budget to bring us closer to curing diseases like cancer and diabetes and to give all of us access to the personalized information we need to keep ourselves and our families healthier.[1] The National Institutes of Health (NIH) and the National Cancer Institute (NCI) will be the major benefactors if the proposed budget for this initiative is approved. A recent article co-authored by Drs. Francis S. Collins and Harold Varmus, directors of the NIH and NCI, respectively, identifies precision medicines critical needs and discusses how the Presidents initiative will help accelerate progress toward a new era of precision medicine.[2] Continue reading this entry

23andMe is not a traditional diagnostics company. Rather than seeking to directly sell its services to health care professionals, 23andMe went straight to the consumer, offering genetic screening and analysis in a mail-order fashion. For ninety-nine dollars, customers only needed to send in a saliva sample and the company would analyze the customers genetic information, interpret and report the results directly to the consumer, bypassing the physician or genetic counselor. Continue reading this entry

Late last year, the USPTO issued its modified and revised 2014 Interim Guidance on Patent Subject Matter Eligibility (Interim Guidance) to assist patent examiners and the public in determining if a claim presented for examination is patent-eligible in view of recent U.S. Supreme Court decisions, namely Alice Corp., Myriad, and Mayo. In addition to streamlining the analysis of patent claims directed to any one of the judicial exceptions to patent-eligibility (abstract ideas, laws of nature and physical phenomena), the USPTO provided illustrative examples to be used in combination with the Interim Guidance. One such example discussed the patent-eligibility of claims directed to stem cells or regenerative medicine. Fortunatelyfor these industries, application of the Interim Guidance as discussed in the example finds that many stem cell technologies are patent-eligible. Continue reading this entry

Personalized medicine has a friend in high places. President Obama recently announced an initiative to support precision or personalized medicine. In very general terms, the President stated during his 2015 State of the Union address that he wanted the United States to lead a new era of medicine an era that delivers the right treatment at the right time. Continue reading this entry

Follow this link:
Personalized Medicine Bulletin Personalized Medicine ...

Mendoza Foresight: Personalized Medicine

By: Emily Holz

Read this article:
Mendoza Foresight: Personalized Medicine - Video

Populations to People: The Practice of Personalized Medicine
Presented by Euan A. Ashley, MD, PhD, RF #39;06 Associate Professor of Medicine and of Genetics Co-Director, Stanford Clinical Genomics Service.

By: StanfordMedAlumni

Go here to read the rest:
Populations to People: The Practice of Personalized Medicine - Video

Personalized Medicine Video
1) Zach, your boredom amuses me =_=;; 2) Our acting, creativity, preparation, and accurate information...sucks T^T 3) Kayla #39;s piano at the end :D.

By: Brian Ho

Read the original post:
Personalized Medicine Video - Video

Mihai Diamandopol at Bucharest Forum Healthcare 2015
Mihai Diamandopol, General Manager, ABBVIE Romania, on Personalized Medicine The Long Road ahead for Medical Research and Development panel, at Bucharest Forum Healthcare 2015, ...

By: Institutul Aspen Romania

Continued here:
Mihai Diamandopol at Bucharest Forum Healthcare 2015 - Video

Oana Cuzino at Bucharest Forum Healthcare 2015
Oana Cuzino, MD, Healthcare Media Expert, TV Producer, MediaPro Group, on Personalized Medicine The Long Road ahead for Medical Research and Development panel, at Bucharest Forum...

By: Institutul Aspen Romania

Go here to read the rest:
Oana Cuzino at Bucharest Forum Healthcare 2015 - Video

Personalized Medicine: Targeting the Tumor - Nevena Damjanov, MD

By: johnbrunedigital1

More here:
Personalized Medicine: Targeting the Tumor - Nevena Damjanov, MD - Video

Dr. Goldkorn - Next Generation Sequencing (NGS) the Future of Personalized Medicine in Oncology
Amir Goldkorn, MD, is the Assistant Professor of Medicine at the USC Norris Comprehensive Cancer Center. Listen to his perspective about next generation sequencing (NGS), and the future of...

By: Janssen Diagnostics

Visit link:
Dr. Goldkorn - Next Generation Sequencing (NGS) & the Future of Personalized Medicine in Oncology - Video

Personalized Medicine: Genome Mapping
Understand how an analysis of your genes can reveal so much about your health.

By: Hope Channel North America

View original post here:
Personalized Medicine: Genome Mapping - Video

Heart chip beats towards better drug screening, personalized medicine
Video credit: Reuters.

By: Thanh Nien News NewsVietnam.org

Read more here:
Heart chip beats towards better drug screening, personalized medicine - Video

Accelerating the Promise of Personalized Medicine
CNN #39;s Chief Medical Correspondent Dr. Sanjay Gupta extends his "60 Minutes Overtime" conversation with renowned Dr. Patrick Soon-Shiong, who is developing the revolutionary approach to cancer...

By: Lake Nona Institute

Go here to read the rest:
Accelerating the Promise of Personalized Medicine - Video

Personalized Medicine for Melanoma Aims at Keeping the Immune System Awake
One out of 10 people will be diagnosed with melanoma over their lifetime. While this used to be a death sentence of only months, research has made great strides over the last decade, extending...

By: Patient Power

Follow this link:
Personalized Medicine for Melanoma Aims at Keeping the Immune System Awake - Video

Bringing Genomics Home Vancouver 2015 - Brad Popovich
Brad Popovich PhD, Chief Scientific Officer, Genome BC Brad introduces the crowd and speaks about "In the next five years how will genomics impact personalized medicine in BC?"

By: Genome BC

Continued here:
Bringing Genomics Home Vancouver 2015 - Brad Popovich - Video

Dr Decker PGx Case Study

By: Indiana Institute for Personalized Medicine (IIPM)

Continued here:
Dr Decker PGx Case Study - Video

Dr Vuppalanchi Pharmacogenomic in Gastroenterology and Heptology

By: Indiana Institute for Personalized Medicine (IIPM)

Excerpt from:
Dr Vuppalanchi Pharmacogenomic in Gastroenterology and Heptology - Video